469.71
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TMO?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$466.70
Offen:
$469.15
24-Stunden-Volumen:
2.68M
Relative Volume:
1.19
Marktkapitalisierung:
$174.55B
Einnahmen:
$45.20B
Nettoeinkommen (Verlust:
$6.88B
KGV:
25.82
EPS:
18.1925
Netto-Cashflow:
$6.75B
1W Leistung:
-10.80%
1M Leistung:
-4.20%
6M Leistung:
-17.95%
1J Leistung:
+10.09%
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Firmenname
Thermo Fisher Scientific Inc
Sektor
Branche
Telefon
(781) 622-1000
Adresse
168 THIRD AVENUE, WALTHAM, MA
Compare TMO vs DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
TMO
Thermo Fisher Scientific Inc
|
469.71 | 173.44B | 45.20B | 6.88B | 6.75B | 18.19 |
|
DHR
Danaher Corp
|
177.25 | 126.39B | 24.78B | 3.68B | 5.29B | 5.1743 |
|
IDXX
Idexx Laboratories Inc
|
565.93 | 44.55B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
115.55 | 32.34B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
309.87 | 30.55B | 3.17B | 642.63M | 516.49M | 10.77 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-27 | Eingeleitet | DZ Bank | Buy |
| 2025-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-12-09 | Eingeleitet | Goldman | Buy |
| 2025-12-08 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-12-01 | Hochstufung | HSBC Securities | Hold → Buy |
| 2025-09-11 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-08-19 | Eingeleitet | William Blair | Outperform |
| 2025-07-24 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-07-11 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-07-09 | Herabstufung | UBS | Buy → Neutral |
| 2025-01-10 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2024-12-23 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-10-01 | Eingeleitet | Stephens | Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-03-18 | Fortgesetzt | Citigroup | Neutral |
| 2024-01-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-01-08 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-10-26 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-10-25 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-09-06 | Fortgesetzt | Citigroup | Buy |
| 2023-07-19 | Eingeleitet | Raymond James | Outperform |
| 2023-07-19 | Bestätigt | Robert W. Baird | Outperform |
| 2023-07-13 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2023-04-04 | Bestätigt | Barclays | Overweight |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-10-27 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-08-25 | Eingeleitet | Credit Suisse | Neutral |
| 2022-04-25 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2022-01-26 | Fortgesetzt | Barclays | Overweight |
| 2021-10-20 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-16 | Eingeleitet | The Benchmark Company | Buy |
| 2021-03-18 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-03 | Eingeleitet | Barclays | Overweight |
| 2021-01-08 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-02 | Eingeleitet | Goldman | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-09-14 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-08-20 | Fortgesetzt | JP Morgan | Overweight |
| 2020-07-15 | Hochstufung | Cleveland Research | Neutral → Buy |
| 2020-07-07 | Bestätigt | Needham | Buy |
| 2020-04-23 | Bestätigt | Needham | Buy |
| 2020-01-31 | Bestätigt | Needham | Buy |
| 2020-01-22 | Eingeleitet | Credit Suisse | Neutral |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-07-25 | Bestätigt | Needham | Buy |
| 2019-07-16 | Herabstufung | Needham | Strong Buy → Buy |
| 2019-05-30 | Eingeleitet | Wolfe Research | Outperform |
| 2019-05-23 | Bestätigt | Needham | Strong Buy |
| 2019-04-22 | Bestätigt | Needham | Strong Buy |
| 2019-04-16 | Bestätigt | BofA/Merrill | Buy |
Alle ansehen
Thermo Fisher Scientific Inc Aktie (TMO) Neueste Nachrichten
Medpace or Thermo Fisher Scientific: Which Stock Has More Upside? - Trefis
Stifel Adjusts Price Target on Thermo Fisher Scientific to $600 From $700, Maintains Buy Rating - marketscreener.com
Leerink Partners Adjusts Price Target on Thermo Fisher Scientific to $600 From $650, Maintains Outperform Rating - marketscreener.com
JPMorgan Adjusts Price Target on Thermo Fisher Scientific to $600 From $710, Maintains Overweight Rating - marketscreener.com
Thermo Fisher Scientific Inc. (NYSE:TMO) Q1 2026 Earnings Call Transcript - Insider Monkey
Thermo Fisher Scientific Q1 Earnings Call Highlights - Yahoo Finance
Clinical Trial Data Visualization Research Report 2026: $1.82 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F - GlobeNewswire Inc.
Thermo Fisher Scientific Inc. $TMO is Davis Rea LTD.'s 6th Largest Position - MarketBeat
Thermo Fisher Scientific Inc (TMO) Q1 2026 Earnings Call Highlig - GuruFocus
Why Thermo Fisher (TMO) Stock Is Nosediving - Yahoo Finance
Thermo Fisher Scientific: Why A Slow Q1 Does Not Reflect The Growth Opportunities - Seeking Alpha
Thermo Fisher Earnings Call Signals Confident Outlook - TipRanks
A Look at Thermo Fisher Scientific Inc (TMO) After 9.2% Decline -- GF Value $579.60 vs Price $466.70 - GuruFocus
Organic Revenue Flat, Stock Price Drops for Thermo Fisher Scientific - WFMZ.com
Thermo Fisher Scientific Inc. stock falls Thursday, underperforms market - MarketWatch
Thermo Fisher Flags 'Modest Inflation' Risk Amid Middle East Tensions - Benzinga
Thermo Fisher CEO says onshoring push will bring a ‘tailwind’ for the Waltham company - The Business Journals
Thermo Fisher Scientific Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Thermo Fisher Scientific (TMO) Raises Full-Year Guidance After S - GuruFocus
Thermo Fisher projects 2026 adjusted EPS of $24.64-$25.12 as it raises revenue outlook to $47.3B-$48.1B - MSN
Thermo Fisher exec says we expect the conflict in the Middle East to create some modest level of inflationary pressureconf call - marketscreener.com
Thermo Fisher Kicks Off 2026 with New Instruments, AI Push, and a Warning on Rising Lab Costs - Lab Manager
Thermo Fisher says US academic demand to stay weak, flags inflation risks from Iran war - Reuters
Thermo Fisher falls after earnings top estimates, but growth concerns persist - Yahoo Finance
Thermo Fisher (TMO) Q1 2026 Earnings Transcript - The Motley Fool
Thermo Fisher slides as investors weigh soft organic growth and weaker diagnostic/instrument trends despite Q1 beat - Quiver Quantitative
Thermo Fisher Scientific (TMO) Reports Q1 2026 Earnings, Faces M - GuruFocus
Thermo Fisher Profit Up, Warns of Inflation from Iran War -- Update - marketscreener.com
Tranche Update on Thermo Fisher Scientific Inc.'s Equity Buyback Plan announced on November 6, 2025. - marketscreener.com
Thermo Fisher (TMO) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance Singapore
Thermo Fisher Scientific Q1 2026 Earnings Call: Complete Transcript - Benzinga
Thermo Fisher stock drops despite Q1 beat (update) (TMO:NYSE) - Seeking Alpha
Thermo Fisher Scientific Reports First Quarter 2026 Results - PharmiWeb.com
Thermo Fisher (TMO) Reports Strong Q1 2026 Results, Shares Drop Ahead of Full-Year Outlook - GuruFocus
Thermo Fisher dips in premarket despite Q1 earnings beat - Yahoo Finance
Does Thermo Fisher Scientific (NYSE:TMO) Deserve A Spot On Your Watchlist? - Yahoo Finance
Thermo Fisher ranks sixth by Quant as stock falls on Q1 results (TMO:NYSE) - Seeking Alpha
Thermo Fisher Scientific (TMO) Q1 Beat: EPS $4.43 vs $4.17, Reve - GuruFocus
Thermo Fisher Scientific (NYSE:TMO) Beats Q1 Estimates But Stock Drops in Pre-Market - ChartMill
Thermo Fisher Scientific (TMO) Q1 Earnings and Revenues Top Estimates - Yahoo Finance
Thermo Fisher (TMO) Reports Strong Q1 Revenue Exceeding Expectat - GuruFocus
Thermo Fisher Scientific slides 3% despite solid financial report 📉 - XTB.com
Thermo Fisher posts quarterly results beat as lab products, biopharma services grow - Yahoo Finance
THERMO FISHER SCIENTIFIC ($TMO) Releases Q1 2026 Earnings - Quiver Quantitative
Thermo Fisher Posts Higher 1Q Profit, Revenue - marketscreener.com
TMO (Thermo Fisher Scientific Inc) Q4 2025 EPS narrowly beats estimates, shares gain 2.05 percent on favorable investor sentiment.Expert Verified Trades - Xã Thanh Hà
Thermo Fisher slips in premarket despite beating Q1 forecasts By Investing.com - Investing.com Canada
Thermo Fisher’s (NYSE:TMO) Q1 CY2026 Sales Top Estimates - TradingView
Thermo Fisher Scientific reports Q1 2026: Revenue $11.01B, GAAP diluted EPS $4.43, Adjusted EPS $5.44 - TradingView
Thermo Fisher: Q1 Earnings Snapshot - KTVB
Earnings Flash (TMO) Thermo Fisher Scientific Inc. Reports Q1 Revenue $11.01B, vs. FactSet Est of $10.86B - marketscreener.com
Finanzdaten der Thermo Fisher Scientific Inc-Aktie (TMO)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):